Critical Analysis: Spruce Biosciences (NASDAQ:SPRB) & eFFECTOR Therapeutics (NASDAQ:EFTR)

eFFECTOR Therapeutics (NASDAQ:EFTR – Get Free Report) and Spruce Biosciences (NASDAQ:SPRB – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Institutional & Insider Ownership

57.7% of eFFECTOR Therapeutics shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 4.7% of eFFECTOR Therapeutics shares are held by company insiders. Comparatively, 6.9% of Spruce Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares eFFECTOR Therapeutics and Spruce Biosciences”s gross revenue, earnings per share (EPS) and valuation.

eFFECTOR Therapeutics has higher earnings, but lower revenue than Spruce Biosciences. Spruce Biosciences is trading at a lower price-to-earnings ratio than eFFECTOR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares eFFECTOR Therapeutics and Spruce Biosciences’ net margins, return on equity and return on assets.

Risk & Volatility

eFFECTOR Therapeutics has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 3.62, meaning that its stock price is 262% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for eFFECTOR Therapeutics and Spruce Biosciences, as reported by MarketBeat.

Spruce Biosciences has a consensus price target of $170.10, indicating a potential upside of 169.83%. Given Spruce Biosciences’ stronger consensus rating and higher probable upside, analysts clearly believe Spruce Biosciences is more favorable than eFFECTOR Therapeutics.

Summary

Spruce Biosciences beats eFFECTOR Therapeutics on 7 of the 12 factors compared between the two stocks.

About eFFECTOR Therapeutics

(Get Free Report)

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

About Spruce Biosciences

(Get Free Report)

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.